spinal
muscular
atrophi
sma
neurodegen
diseas
associ
sever
muscl
atrophi
weak
limb
trunk
report
interim
efficaci
safeti
outcom
march
children
genet
diagnos
sma
first
receiv
nusinersen
infanc
presymptomat
ongo
phase
multisit
openlabel
singlearm
nurtur
trial
fifteen
children
two
copi
three
copi
last
visit
children
median
rang
month
age
past
expect
age
symptom
onset
sma
type
ii
aliv
none
requir
tracheostomi
perman
ventil
four
particip
two
copi
util
respiratori
support
hday
consecut
day
initi
acut
revers
ill
particip
achiev
abil
sit
without
support
achiev
walk
assist
achiev
walk
independ
eight
infant
advers
event
consid
possibl
relat
nusinersen
studi
investig
result
repres
median
year
follow
emphas
import
proactiv
treatment
nusinersen
immedi
establish
genet
diagnosi
sma
presymptomat
infant
emerg
newborn
screen
effort
spinal
muscular
atrophi
sma
autosom
recess
neurodegen
diseas
associ
progress
often
sever
muscl
weak
atrophi
lead
caus
death
infant
sma
caus
homozyg
delet
sma
patient
compound
heterozyg
mutat
sma
patient
surviv
motor
neuron
gene
prevent
product
fulllength
function
smn
protein
paralog
gene
undergo
aberr
splice
produc
mostli
truncat
dysfunct
protein
symptom
onset
often
occur
infanc
earli
childhood
although
onset
adulthood
mildest
form
symptom
gener
sever
earlier
onset
individu
develop
sma
symptomfre
period
birth
differ
durat
everi
individu
sma
divid
four
major
subtyp
base
age
symptom
onset
maximum
motor
function
achiev
maximum
motor
function
achiev
influenc
sma
treatment
mani
infant
infantileonset
sma
children
lateronset
sma
treat
nusinersen
endear
cherish
studi
respect
achiev
motor
function
incongru
expect
sma
subtyp
base
copi
number
age
symptom
onset
prior
onset
symptom
marker
must
reli
upon
diagnosi
classif
predict
sma
subtyp
gene
copi
number
roughli
correl
diseas
sever
increas
number
gene
copi
typic
lead
increas
amount
function
smn
protein
milder
phenotyp
among
individu
disrupt
therefor
expect
develop
sma
symptom
approxim
individu
two
copi
gene
predict
develop
type
form
sma
approxim
three
copi
gene
predict
develop
sma
type
ii
addit
phosphoryl
neurofila
heavi
chain
pnfh
level
recent
shown
promis
biomark
diseas
activ
treatment
respons
individu
sma
pnfh
neuronspecif
cytoskelet
structur
protein
releas
plasma
cerebrospin
fluid
csf
axon
damag
endear
cherish
studi
concentr
pnfh
found
correl
baselin
clinic
characterist
indic
diseas
sever
furthermor
pnfh
concentr
declin
rapidli
stabil
lower
level
follow
nusinersen
treatment
manner
seen
sham
control
group
nusinersen
antisens
oligonucleotid
alter
splice
premrna
promot
express
fulllength
smn
protein
first
diseasemodifi
treatment
approv
sma
clinic
studi
rang
symptomat
children
across
sever
sma
popul
nusinersen
demonstr
signific
clinic
meaning
benefit
assess
achiev
motor
mileston
measur
motor
function
surviv
infantileonset
sma
along
favor
safeti
profil
importantli
subgroup
analys
shamcontrol
studi
infantileonset
endear
lateronset
cherish
sma
indic
greater
improv
motor
function
follow
nusinersen
treatment
observ
rel
shorter
diseas
durat
treatment
initi
suggest
earlier
treatment
may
lead
better
clinic
outcom
nurtur
ongo
phase
openlabel
studi
aim
evalu
safeti
efficaci
nusinersen
prevent
profoundli
attenu
sever
sma
initi
prior
onset
symptom
infant
enrol
nurtur
genet
confirm
sma
week
old
first
dose
consid
like
develop
sma
type
type
ii
base
upon
gene
copi
number
expect
concord
phenotyp
affect
sibl
base
previou
studi
absenc
treatment
mani
infant
would
expect
achiev
independ
sit
like
develop
sma
type
would
expect
ever
walk
independ
would
also
expect
requir
respiratori
intervent
would
surviv
beyond
earli
year
nurtur
ongo
phase
openlabel
singlearm
multin
studi
evalu
longterm
safeti
efficaci
intrathec
nusinersen
infant
initi
treatment
earli
prior
onset
clinic
sign
sma
given
expect
infant
genet
diagnos
sma
without
function
copi
gene
two
three
copi
gene
develop
sever
fatal
symptom
first
year
life
intern
control
group
consid
unnecessari
ethic
unjustifi
nurtur
consist
treatment
period
posttreat
followup
evalu
key
elig
criteria
age
week
first
dose
genet
document
sma
biallel
delet
protein
disabl
mutat
gene
two
three
copi
gene
baselin
compound
muscl
action
potenti
cmap
amplitud
mv
protocol
amend
septemb
version
baselin
ulnar
cmap
amplitud
mv
absenc
hypoxemia
clinic
sign
symptom
suggest
sma
particip
receiv
nusinersen
mg
administ
intrathec
inject
lumbar
punctur
nusinersen
treatment
regimen
consist
four
load
dose
administ
day
follow
mainten
dose
everi
day
five
year
fig
intentiontotreat
popul
infant
receiv
dose
studi
drug
n
infant
attend
opportun
attend
visit
b
infant
treat
nusinersen
mg
infant
receiv
scale
equival
dose
protocol
revis
march
interim
analysi
ongo
nurtur
studi
report
data
march
data
cut
time
interim
analysi
nurtur
infant
median
month
age
past
expect
age
symptom
onset
sma
type
ii
nurtur
trial
take
place
activ
studi
site
seven
countri
studi
approv
local
ethic
committe
particip
site
conduct
accord
intern
council
harmon
ich
guidelin
good
clinic
practic
declar
helsinki
written
inform
consent
obtain
parent
legal
guardian
studi
particip
accord
local
practic
regul
primari
endpoint
nurtur
time
death
respiratori
intervent
invas
noninvas
h
per
day
continu
day
tracheostomi
secondari
endpoint
report
interim
analysi
includ
proport
particip
aliv
attain
motor
mileston
assess
world
health
organ
criteria
attain
motor
mileston
hammersmith
infant
neurolog
examin
section
chang
baselin
children
hospit
philadelphia
infant
test
neuromuscular
disord
chop
intend
motor
function
scale
chang
baselin
growth
paramet
weight
agelength
head
circumfer
chest
circumfer
headtochest
circumfer
ratio
arm
circumfer
proport
particip
develop
clinic
manifest
sma
month
age
defin
follow
condit
ageadjust
weight
percentil
decreas
major
weight
growth
curv
percentil
compar
baselin
percutan
gastric
tube
placement
nutrit
support
month
age
b
failur
achiev
sit
without
support
stand
assist
handsandkne
crawl
age
month
c
failur
achiev
mileston
defin
age
month
failur
achiev
walk
assist
stand
alon
walk
alon
age
month
secondari
safeti
endpoint
includ
incid
advers
event
ae
seriou
advers
event
sae
chang
baselin
clinic
laboratori
paramet
electrocardiogram
ecg
vital
sign
neurolog
examin
neurolog
statu
behavior
particip
age
month
standard
neurolog
exam
particip
age
month
exploratori
endpoint
includ
chang
baselin
cmap
amplitud
time
death
perman
ventil
defin
hday
continu
day
absenc
acut
revers
event
tracheostomi
time
death
ventil
hday
continu
day
tracheostomi
plasma
csf
pnfh
concentr
chang
time
also
assess
interim
analysi
follow
clinic
assess
perform
evalu
nusinersen
efficaci
surviv
respiratori
event
motor
mileston
achiev
neurolog
evalu
chop
intend
motor
function
scale
growth
paramet
ulnar
peron
cmap
amplitud
plasmacsf
pnfh
level
list
studi
visit
data
collect
studi
assess
provid
supplementari
tabl
achiev
motor
mileston
evalu
use
criteria
assess
tool
motor
mileston
set
six
mileston
sit
without
support
stand
assist
handsandkne
crawl
walk
assist
stand
alon
walk
alon
expect
attain
age
month
healthi
children
motor
mileston
assess
physic
therapist
age
first
achiev
mileston
record
caregiv
hine
quantifi
threepart
assess
evalu
neurolog
statu
section
develop
motor
function
section
behavior
section
neurolog
item
assess
includ
suckingswallow
abil
assess
cranial
nerv
function
score
rang
higher
score
indic
better
function
measur
development
progress
eight
motor
mileston
voluntari
grasp
abil
kick
supin
posit
head
control
roll
sit
crawl
stand
walk
total
score
rang
higher
score
indic
better
motor
function
score
assess
day
chop
intend
motor
assess
develop
evalu
motor
skill
infant
sma
type
higher
score
indic
better
motor
function
chop
intend
assess
particip
reach
maximum
score
assess
motor
function
assess
perform
train
clinic
evalu
cmap
amplitud
electrophysiolog
techniqu
reflect
mass
excit
muscl
tissu
depolar
whole
nerv
stimul
sma
relat
approxim
number
motor
neuron
innerv
muscl
ulnar
cmap
amplitud
wellvalid
method
track
diseas
progress
sma
measur
growth
paramet
includ
length
weightforag
lengthforag
weightforlength
head
circumfer
chest
circumfer
headtochest
circumfer
ratio
arm
circumfer
child
growth
standard
use
determin
percentil
paramet
pnfh
level
recent
shown
potenti
biomark
diseas
sever
respons
treatment
individu
sma
plasma
csf
sampl
test
pnfh
pnfh
level
summar
geometr
mean
nurtur
infant
copi
number
compar
level
report
infant
without
sma
age
year
geometr
mean
use
appropri
account
underli
distribut
data
sampl
individu
donat
boston
children
hospit
boston
confirm
individu
known
neurolog
musculoskelet
disord
chronic
ill
pnfh
level
measur
use
pnfh
enzymelink
lectin
assay
proteinsimpl
safeti
assess
includ
treatmentemerg
ae
monitor
neurolog
examin
physic
examin
vital
sign
measur
puls
oximetri
ecg
laboratori
test
hematolog
blood
chemistri
urinalysi
coagul
perform
train
physician
ancillari
medic
profession
possibl
comparison
surviv
motor
mileston
achiev
made
nurtur
particip
nonnusinersentr
sibl
sma
noninvas
data
collect
sibl
includ
gene
copi
number
sibl
sma
histori
sibl
treatment
histori
time
death
respiratori
intervent
proport
particip
aliv
proport
particip
achiev
motor
mileston
proport
particip
develop
clinic
manifest
sma
safeti
analys
analyz
studi
particip
receiv
dose
nusinersen
intenttotreat
popul
efficaci
analys
perform
interim
efficaci
set
compris
dose
particip
attend
opportun
attend
target
visit
analysi
efficaci
set
secondari
endpoint
assess
age
month
proport
particip
aliv
proport
achiev
motor
mileston
age
month
estim
use
kaplanmei
method
chop
intend
total
score
total
motor
mileston
score
chang
growth
paramet
ulnar
peron
cmap
amplitud
pnfh
concentr
summar
use
descript
statist
proport
particip
develop
clinic
manifest
sma
day
assess
day
assess
report
correspond
wilson
score
confid
interv
ci
continu
correct
age
motor
mileston
achiev
determin
use
caregiverreport
date
confirm
subsequ
studi
visit
physic
therapist
identifi
earli
predictor
motor
function
spearman
correl
coeffici
calcul
specif
relationship
particip
characterist
baselin
end
load
dose
period
day
age
first
dose
nusinersen
gestat
age
plasma
pnfh
level
weight
age
chop
intend
total
score
motor
mileston
total
score
ulnar
cmap
amplitud
futur
motor
function
day
total
motor
mileston
score
age
achiev
walk
alon
evalu
statist
softwar
sa
r
version
cari
nc
use
summari
statist
analys
total
infant
screen
infant
two
copi
three
copi
met
elig
criteria
enrol
studi
five
infant
inelig
one
diagnosi
sma
one
two
three
copi
gene
three
ulnar
cmap
amplitud
equal
one
mv
screen
two
also
clinic
sign
symptom
suggest
sma
first
particip
initi
visit
may
enrol
complet
februari
data
cutoff
particip
withdrawn
studi
discontinu
treatment
median
rang
age
first
dose
nusinersen
among
enrol
infant
month
baselin
characterist
copi
number
shown
tabl
median
rang
chop
intend
total
score
total
motor
mileston
score
respect
twocopi
particip
n
respect
threecopi
particip
n
twentyfour
particip
consent
collect
plasma
csf
futur
investig
possibl
biomark
sma
diseas
baselin
plasma
valu
unavail
two
particip
baselin
csf
valu
unavail
one
particip
geometr
mean
ci
plasma
pnfh
concentr
pgml
twocopi
particip
n
pgml
threecopi
particip
n
geometr
mean
ci
csf
pnfh
concentr
pgml
twocopi
particip
n
pgml
threecopi
particip
n
nineteen
nurtur
particip
sibl
sma
total
full
sibl
two
half
sibl
sibl
eight
two
copi
eight
three
copi
eight
undocu
number
copi
one
sibl
relat
two
nurtur
particip
set
twin
interim
analysi
nurtur
particip
aliv
none
requir
perman
ventil
median
time
death
respiratori
intervent
invas
noninvas
ventil
hday
continu
day
tracheostomi
could
estim
event
four
infant
two
copi
util
respiratori
intervent
h
per
day
continu
day
fig
initi
respiratori
intervent
acut
revers
ill
last
studi
day
prior
data
cutoff
two
infant
longer
util
respiratori
intervent
infant
previous
receiv
respiratori
intervent
h
per
day
total
day
cours
studi
two
infant
continu
receiv
respiratori
intervent
two
h
per
day
respect
last
studi
day
prior
data
cutoff
infant
receiv
respiratori
intervent
h
per
day
total
day
respect
cours
studi
infant
receiv
respiratori
intervent
cours
studi
achiev
motor
mileston
data
cutoff
nurtur
infant
achiev
motor
mileston
sit
without
support
two
copi
three
copi
achiev
walk
assist
two
copi
three
copi
achiev
walk
alon
siteor
caregiverreport
age
first
achiev
motor
mileston
shown
fig
median
ci
age
first
achiev
sit
without
support
walk
assist
walk
alon
two
copi
particip
month
month
month
respect
three
copi
median
ci
age
first
achiev
sit
without
support
walk
assist
walk
alon
month
month
month
respect
motor
mileston
total
score
also
increas
time
particip
regardless
copi
number
mean
rang
total
score
increas
baselin
last
observ
visit
includ
day
particip
two
copi
three
copi
mean
score
infant
two
three
copi
approach
scale
maximum
point
threecopi
particip
approach
maximum
earlier
particip
two
copi
fig
motor
function
mean
chop
intend
total
score
rose
steadili
baselin
approxim
day
remain
stabl
time
fig
last
visit
mean
rang
chop
intend
total
score
two
copi
three
copi
time
interim
analysi
particip
copi
copi
achiev
maximum
score
fig
b
beyond
day
chop
intend
total
score
appear
constrain
plateau
ceil
effect
point
longer
assess
particip
achiev
maximum
score
howev
continu
improv
observ
mileston
outcom
last
observ
visit
includ
day
nurtur
particip
abil
suck
swallow
measur
neurolog
assess
twentytwo
particip
two
copi
three
copi
achiev
maximum
score
good
suck
swallow
three
infant
fig
siteor
caregiverreport
age
first
motor
mileston
achiev
surviv
motor
neuron
world
health
organ
caregiverreport
achiev
confirm
studi
site
next
studi
visit
ye
respons
b
motor
mileston
window
achiev
determin
base
multicent
growth
refer
studi
window
achiev
healthi
children
two
copi
achiev
score
poor
suck
andor
swallow
three
gastrostomi
tube
place
clinic
manifest
sma
proport
two
copi
particip
protocoldefin
symptom
sma
ci
n
total
age
month
ci
n
total
age
month
proport
three
copi
particip
protocoldefin
symptom
sma
ci
n
total
age
month
ci
n
total
age
month
seven
infant
develop
protocoldefin
symptom
sma
month
two
copi
continu
grow
achiev
motor
mileston
inconsist
type
sma
mileston
attain
sibl
sma
seven
sit
without
support
five
walk
without
assist
four
walk
alon
six
seven
particip
sibl
sma
none
sibl
achiev
sit
independ
requir
tracheostomi
andor
die
month
age
seven
infant
clinic
manifest
sma
age
month
includ
three
particip
poor
suckswallow
reflex
gastrostomi
tube
place
three
infant
undoubtedli
exceed
expect
two
copi
type
predict
phenotyp
achiev
abil
sit
independ
achiev
motor
mileston
slower
pace
particip
two
copi
studi
three
particip
abl
stand
assist
two
abl
walk
assist
one
achiev
walk
alon
two
infant
receiv
respiratori
intervent
last
visit
baselin
pnfh
level
higher
presymptomat
infant
sma
compar
nonsma
infant
significantli
higher
particip
two
copi
compar
three
copi
plasma
p
csf
p
geometr
mean
plasma
pnfh
level
healthi
infant
year
age
pgml
median
rang
pgml
n
fig
presymptomat
infant
sma
geometr
mean
plasma
pnfh
level
declin
rapidli
load
phase
nusinersen
treatment
stabil
fig
b
similar
pattern
declin
follow
stabil
observ
geometr
mean
csf
pnfh
level
supplementari
fig
ulnar
nerv
cmap
amplitud
baselin
mv
mv
particip
two
three
copi
respect
p
remain
stabl
time
supplementari
fig
similar
result
observ
peron
nerv
tibiali
anterior
cmap
amplitud
baselin
peron
cmap
amplitud
two
versu
three
copi
particip
p
supplementari
fig
correl
calcul
identifi
earliest
strongest
predictor
motor
function
among
baselin
characterist
analyz
baselin
plasma
pnfh
level
strongest
predictor
total
motor
mileston
score
day
r
p
n
age
achiev
walk
alon
r
p
n
analysi
particip
characterist
day
plasma
pnfh
level
day
best
predictor
futur
motor
function
achiev
overal
popul
plasma
pnfh
level
day
significantli
correl
total
motor
mileston
score
day
r
p
n
achiev
motor
mileston
walk
alon
r
p
n
lower
plasma
pnfh
level
day
associ
earlier
achiev
walk
alon
fig
particip
copi
day
weight
age
r
p
n
day
cmap
amplitud
r
p
n
correl
total
motor
mileston
achiev
day
similar
result
observ
age
achiev
walk
alon
associ
day
weight
age
day
cmap
amplitud
achiev
walk
alon
shown
supplementari
fig
b
plasma
pnfh
level
day
evalu
relationship
individu
without
sma
motor
mileston
achiev
outcom
plasma
sampl
analyz
nonsma
individu
rang
age
year
individu
plasma
pnfh
level
rang
pgml
pgml
pgml
nurtur
day
select
analysi
base
age
rang
nonsma
individu
twentytwo
nurtur
particip
record
measur
day
plasma
pnfh
level
copi
copi
result
pgml
nonsma
individu
year
age
among
nurtur
particip
children
initi
ventil
support
n
met
protocol
definit
clinic
manifest
sma
day
n
andor
delay
achiev
sit
walk
alon
per
percentil
window
day
plasma
pnfh
level
pgml
nonsma
individu
year
age
ae
report
nurtur
particip
tabl
twenti
particip
ae
mild
moder
sever
ae
consid
definit
relat
studi
drug
investig
ae
consid
investig
possibl
relat
studi
drug
infant
resolv
despit
continu
treatment
except
one
case
proteinuria
clonu
ongo
time
data
cutoff
total
sae
report
particip
treatmentemerg
sae
particip
includ
tendon
disord
dehydr
n
bronchiti
choke
pneumonia
n
pneumonia
n
mycoplasm
pneumonia
n
viral
upper
respiratori
tract
infect
n
abdomin
distens
respiratori
distress
dehydr
enteroviru
infect
corona
viru
infect
respiratori
syncyti
viru
bronchiol
bacteri
pneumonia
acut
respiratori
failur
respiratori
failur
tachycardia
viral
gastroenter
pneumonia
n
respiratori
distress
respiratori
syncyti
viru
bronchiol
aspir
pneumonia
pneumonia
n
failur
thrive
n
urinari
tract
infect
n
pyrexia
pneumonia
pneumococc
pneumonia
pseudomon
pneumonia
upper
respiratori
tract
infect
n
respiratori
syncyti
viru
infect
n
upper
respiratori
tract
infect
n
sae
relat
studi
drug
lumbar
punctur
procedur
gener
well
toler
eight
particip
event
determin
investig
possibl
relat
definit
relat
lumbar
punctur
procedur
traumat
lumbar
punctur
n
vomit
n
subdur
hematoma
postprocedur
discomfort
n
headach
n
postlumbar
punctur
procedur
syndrom
lower
lumbar
spinal
canal
hematoma
hypertens
n
postprocedur
swell
n
extradur
hematoma
tachycardia
weightbear
difficulti
muscular
weak
n
epidur
hemorrhag
spinal
subarachnoid
hemorrhag
tachycardia
hyperreflexia
n
five
hemorrhag
near
thecal
space
four
particip
occur
set
multipl
lumbar
punctur
attempt
event
occur
particip
week
old
none
context
thrombocytopenia
lumbar
puncturerel
event
classifi
sae
one
case
postlumbar
punctur
syndrom
occur
first
dose
studi
drug
follow
fail
dose
attempt
clinic
relev
trend
respect
thrombocytopenia
coagul
abnorm
abnorm
liver
kidney
function
test
proteinuria
observ
nurtur
cohort
observ
case
heart
diseas
liver
failur
bacteri
mening
asept
mening
hypersensit
hydrocephalu
alanin
aminotransferas
alt
aspart
aminotransferas
ast
creatin
kinas
creatinin
cystatin
c
platelet
level
remain
stabl
time
supplementari
fig
knowledg
nurtur
first
studi
investig
treatment
target
underli
caus
sma
diseas
presymptomat
period
one
first
two
studi
investig
treatment
presymptomat
sma
result
interim
analysi
repres
median
year
follow
demonstr
substanti
clinic
benefit
infant
two
three
copi
gene
consid
like
develop
type
ii
sma
result
earli
initi
nusinersen
treatment
nurtur
infant
time
interim
analysi
age
month
past
age
symptom
onset
aliv
without
requir
perman
ventil
contrast
natur
histori
untreat
sma
dramat
sma
type
expect
phenotyp
approxim
half
cohort
base
copi
number
die
requir
perman
ventil
averag
month
age
earli
treatment
key
rescu
aris
comparison
nurtur
experi
endear
studi
treatment
nusinersen
initi
symptomat
period
end
endear
studi
nusinersentr
infant
infantileonset
sma
die
requir
perman
ventil
nurtur
particip
aliv
without
perman
ventil
abl
sit
independ
nearli
children
walk
assist
independ
continu
gain
motor
skill
throughout
studi
interv
group
children
two
three
copi
nusinersen
show
rapid
onset
improv
durabl
effect
mean
chop
intend
motor
function
score
result
clearli
incongru
natur
histori
individu
two
three
copi
result
demonstr
treatment
nusinersen
genet
diagnos
infant
sma
presymptomat
period
allow
gain
motor
function
closer
normal
develop
expect
individu
sma
type
ii
motor
mileston
motor
function
achiev
mani
nurtur
infant
also
drastic
discord
untreat
sibl
copi
number
discord
notabl
given
previou
studi
found
sibl
pair
sma
concord
phenotyp
emphas
clinic
meaning
benefit
nusinersen
treatment
presymptomat
period
chop
intend
score
nurtur
infant
similar
observ
healthi
infant
first
three
studi
month
interv
natur
histori
data
healthi
infant
avail
nurtur
infant
chop
intend
score
greatli
exceed
observ
natur
histori
cohort
symptomat
infant
sma
two
copi
cours
studi
mean
sd
declin
point
month
similarli
mean
ulnar
cmap
amplitud
nurtur
infant
remain
stabl
time
particip
two
three
copi
nurtur
amplitud
fell
rapidli
never
higher
mv
natur
histori
cohort
infant
sma
age
month
two
copi
overal
nurtur
infant
initi
treatment
appear
clinic
symptom
earlier
substanti
greater
improv
total
score
infant
children
initi
treatment
symptom
onset
endear
trial
nurtur
infant
also
higher
baselin
chop
intend
score
abl
attain
maximum
nearmaximum
chop
intend
score
quickli
infant
initi
treatment
symptom
onset
differ
popul
age
studi
design
studi
must
kept
mind
interpret
data
differ
score
trajectori
chop
intend
maximum
score
indic
treatment
nusinersen
meaning
impact
clinic
outcom
beyond
seen
treatment
initi
symptom
onset
function
outcom
nurtur
particip
three
copi
gener
better
observ
particip
two
copi
specif
particip
three
copi
achiev
advanc
motor
mileston
includ
walk
independ
wherea
three
particip
two
copi
yet
achiev
mileston
particip
three
copi
also
achiev
higher
mean
chop
intend
total
score
last
observ
visit
particip
two
copi
baselin
chop
intend
score
also
higher
particip
three
copi
versu
two
copi
slight
differ
outcom
patient
three
copi
two
copi
observ
far
exceed
outcom
predict
sma
type
ii
natur
histori
find
highlight
substanti
benefit
earli
therapi
thu
point
valu
earli
diagnosi
populationbas
newborn
screen
nb
method
identifi
presymptomat
individu
treatabl
diseas
aim
provid
opportun
earli
intervent
unit
state
nb
homozyg
delet
exon
gene
ad
recommend
uniform
screen
panel
rusp
juli
nb
program
develop
global
presymptomat
individu
sma
identifi
sever
us
state
nb
program
mani
addit
state
begin
screen
later
addit
nb
effort
sma
ongo
global
support
gener
popul
sever
countri
treatment
algorithm
base
copi
number
sma
posit
infant
identifi
though
nb
recent
develop
group
sma
expert
recommend
infant
two
three
copi
receiv
immedi
treatment
follow
confirmatori
test
addit
recommend
sma
expert
suggest
immedi
treatment
presymptomat
infant
four
copi
nurtur
result
support
immedi
treatment
infant
two
three
copi
support
notion
earlier
treatment
across
spectrum
improv
eventu
outcom
demonstr
endear
cherish
studi
pnfh
level
recent
shown
potenti
biomark
diseas
sever
respons
treatment
individu
sma
concentr
pnfh
endear
cherish
studi
found
correl
sever
baselin
clinic
characterist
indic
diseas
sever
declin
rapidli
treatment
nusinersen
stabil
lower
plateau
level
knowledg
nurtur
first
studi
evalu
pnfh
level
presymptomat
sma
popul
geometr
mean
plasma
csf
level
pnfh
substanti
higher
nurtur
particip
infant
without
sma
within
nurtur
particip
plasma
csf
pnfh
level
significantli
higher
particip
two
versu
three
copi
nusinersen
treatment
initi
pnfh
level
declin
rapidli
load
period
appar
stabil
lower
level
rapid
declin
pnfh
level
suggest
valu
pnfh
potenti
biomark
treatment
respons
smnenhanc
therapi
level
pnfh
plasma
end
nusinersen
load
dose
period
may
predict
futur
motor
function
walk
alon
percentil
expect
age
achiev
high
pnfh
level
measur
onset
clinic
symptom
suggest
pathophysiolog
process
preced
onset
clinic
symptom
whether
releas
pnfh
interstiti
fluid
mark
treatmentrevers
patholog
instead
earli
degener
yet
suffici
magnitud
clinic
appar
yet
unknown
either
case
pretreat
elev
pnfh
level
presymptomat
infant
emphas
valu
nb
initi
worldwid
stress
import
proactiv
intervent
presymptomat
phase
sma
consist
chronic
progress
neurolog
diseas
nusinersen
demonstr
favor
benefitrisk
profil
consist
data
previou
studi
new
safeti
concern
identifi
lumbar
punctur
procedur
gener
well
toler
small
number
hemorrhag
near
thecal
space
occur
set
multipl
lp
attempt
infant
week
old
none
context
thrombocytopenia
care
monitor
hematolog
blood
chemistri
urinalysi
coagul
vital
sign
ecg
demonstr
clinic
relev
trend
relat
nusinersen
treatment
level
creatin
kinas
transaminas
alt
ast
remain
stabl
time
suggest
predisposit
muscl
injuri
hepat
abnorm
though
nurtur
outcom
dramat
key
limit
studi
note
nurtur
openlabel
studi
rel
small
number
particip
sever
particip
untreat
sibl
sma
allow
comparison
motor
function
achiev
natur
histori
formal
assess
perform
sibl
sma
studi
shamcontrol
group
note
infant
variabl
present
across
clinic
measur
baselin
notabl
tendon
reflex
ulnar
cmap
chopintend
howev
although
uniformli
establish
definit
sma
symptom
onset
infant
met
entri
criteria
consid
presymptomat
enrol
accord
investig
chop
intend
score
assess
particip
achiev
maximum
score
time
longer
assess
ceil
effect
chop
intend
score
appar
score
approxim
score
assess
day
assess
later
studi
visit
addit
comparison
chang
chop
intend
score
time
across
nusinersen
clinic
develop
program
must
made
cautious
differ
studi
popul
studi
design
taken
consider
interpret
data
caregiverreport
versu
studi
visit
document
achiev
motor
mileston
could
lead
variat
report
time
achiev
addit
time
followup
vari
among
particip
first
achiev
motor
mileston
may
occur
studi
visit
assess
document
result
nurtur
studi
demonstr
potenti
benefit
initi
nusinersen
presymptomat
period
infant
sma
interim
analysi
mani
infant
children
treat
presymptomat
period
achiev
motor
mileston
timelin
consist
normal
develop
data
demonstr
durabl
effect
median
year
follow
children
continu
make
progress
throughout
studi
evid
sustain
regress
result
exceed
expect
base
natur
histori
sma
phenotyp
particip
sibl
sma
also
repres
treatment
benefit
exceed
observ
treatment
initi
symptomat
period
addit
pnfh
data
nurtur
demonstr
underli
sma
diseas
biolog
activ
presymptomat
period
merit
treatment
result
nurtur
strongli
emphas
need
earli
identif
infant
sma
nb
support
valu
treatment
initi
presymptomat
infant
genet
diagnos
sma
two
three
copi
gene
immedi
sma
diagnosi
conclus
consist
current
recommend
